WASHINGTON, Oct 28 (Reuters) - Severe and sometimes fatal skin reactions have been reported in patients treated with Biogen Idec's (BIIB.O: Quote, Profile, Research) lymphoma drug Zevalin, the U.S. Food and Drug Administration and the company said on Friday.
